Driven by science.
Dedicated to your research.

Ailsa is a research scientist with a PhD from the University of Cambridge and previously worked as an academic clinician in Oxford having completed her medical training in Aberdeen. Ailsa has a deep commitment to improving patient outcomes and has been involved in numerous projects focused on the lived experiences of individuals affected by physical and mental health conditions. Her work includes contributions as a systematic reviewer to NICE Guidelines and Health Technology Assessments, highlighting her critical perspective on stakeholder involvement and evidence-based decision-making. She has also held postdoctoral and senior management positions at GlaxoSmithKline and Pfizer, respectively.

More recently, Ailsa has been involved in projects investigating the role of pathogens in chronic illness and neurodegeneration; she is particularly interested in tick-borne pathogens and the development of improved diagnostic and treatment pathways for affected individuals.

In addition to her research work, Ailsa is a trustee and board member of the Scottish Psychedelics Research Group, helping to raise awareness of emerging therapies in mental health. She is based in the Cairngorms National Park in Scotland.

Gordon is a senior commercial professional with over 30 years’ experience in global life sciences focusing mainly on the IVD point of care sector but has also worked in other areas of life sciences. Most recently, Gordon was Chief Commercial Officer at genedrive plc., the in-vitro diagnostics company based in Manchester, UK, which manufactures the Genedrive point of care instrument and associated molecular assays such as TB and HCV which were targeted at LMICs. Before joining genedrive, Gordon was the Chief Executive Officer at Qnostics Ltd., a molecular control company, and prior to that was the Group Marketing Director of Axis-Shield, in London, UK, responsible for company strategy and direction as well as global sales of the Afinion POC system. It was though, as Marketing Director at Axis-Shield US that Gordon helped launch the highly successful Afinion point of care system initially through Abbott Diagnostics and then through Axis-Shield’s own sales force and PSS. Prior to that he was responsible for the strategic account management for the £9M business which included the Axis-Shield patented Homocysteine, Anti-CCP and Active B12 assays working with Abbott, Bayer, DPC and many more. Gordon also held an advisory position at biosurfit, based in Lisbon, Portugal, where he helped the company raise a €12M investment from the European Investment Bank (EIB).

Gordon is now a Non-Executive Director for EMQN and owner and Director of GRP Consulting Ltd., through which he advises and helps companies in Europe and US commercialise their products globally, as well as undertaking market research and other such services. In addition, Gordon has advised a number of university spins outs, either as a Commercial Advisor to the Board or as an external Consultant, from spin-outs from Glasgow, Strathclyde, Edinburgh, Manchester, Stanford, Oslo, and Lisbon Universities.

Assi is a growth-orientated entrepreneur. Previously, he led Sight Diagnostics’ global growth efforts, working with players from across the healthcare system to accelerate the impact on patients’ lives, scaling their commercial team from scratch.

Before joining Sight, he worked as Data Intelligence Director for the Very Group, the UK’s second-largest pureplay online retailer. He led the consumer and market research, analytics, data strategy, and data science departments through a high-impact transformation and growth.

Before Very, he was an Associate-Partner at McKinsey and Company, where Assi worked with retailers, CPGs, and other consumer-facing companies on growth strategy, commercial improvement and customer experience.

Marc has 30 years of experience in entrepreneurship and R&D in High Technology and Medical Devices, including component design, electronics, micro-mechanics, and complex integrated products, along with seven years of experience as an investor, including Angel and Venture capital. Marc specializes in early deployment made possible by advanced micro-electronics and high technology to bring innovative solutions to the market

Marc currently leads the R&D and early market introduction of the pathology-specific solutions of BioSerenity, a medical device company focused on developing smart healthcare solutions based in Paris.